Abstract
Alternative modernity has become a key notion in the history of science and medicine outside Europe. The aim of the following chapter is to illustrate the fecundity of this concept for addressing the role of non-technological factors in innovation, beyond the “time of empires”. “Modern without being Western” remains a central feature of our present and global fascination for innovation as a driving force of economic and social development. To this purpose this chapter links two issues which have generally been discussed as two unrelated developments in the very recent history of health, pharmacy and industry. First, it discusses the putative crisis of innovation that is presently considered to be a major feature of this critical sector in global capitalism. While the origins of this crisis are often located in non-technological factors, beginning with the changes in the administrative regulation of markets, the articulation of their technological and non-technological aspects warrants closer consideration. Building on an epistemic and social interpretation of the crisis, the chapter then looks at the alternatives that are emerging outside the prevailing Western economy of pharmacy, following the form of alternative modernity associated with the industrialization and globalization of the “traditional” medical systems of Asia. Taking Ayurveda as example, it shows how Indian companies are now reformulating traditional medical knowledge to produce industrial, standardized and simplified poly-herbal remedies targeting biomedically defined disorders, especially the complex chronic disorders that global health now puts high on its agenda. Placing these developments in relation one to the other not only reveal a strong case of innovation beyond technology, but also sheds light on the more general juxtaposition of heterogeneous political economies within what is superficially perceived as a single hegemonic logic of global pharmaceutical capitalism.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
This line of interpretation is actually consistent with a set of studies that have looked at the innovation potential of biotech firms and start ups, albeit with mixed results.
- 2.
US Pharmaceutical Industry Statistics. www.statista.com.
- 3.
Himalaya Ayurveda specialists thus consider that the need for a preparation like Menosan is therefore not the recognition of a previously invisible, unrecognized disorder, but the emergence of a new problem whose roots are in the changing structure of families, in processes of individualization and urbanization. In other words, menopause is a disease of modernity.
References
Achilladelis, B., & Antonakis, N. (2001). The dynamics of technological innovation: The case of the pharmaceutical industry. Research Policy, 30, 535–588.
Arnold, D. (1993). Colonizing the body. State medicine and epidemic disease in 19th century India. University of California Press.
Aronowitz, R. (1999). Making sense of illness. Science, society and diseases. Cambridge: Cambridge University Press.
Attewell, G. (2007). Refiguring Unani Tibb. Plural healing in late colonial India. Hyderabad: Orient Longman.
Banerjee, M. (2009). Power, knowledge, medicine. Ayurvedic pharmaceuticals at home and in the world. Hyderabad: Orient Blackswan.
Bode, M. (2008). Taking traditional knowledge to the market. Hyderabad: Orient Longman.
Booth, B., & Zemmel, R. (2004). Prospects for productivity. Nature Reviews Drug Discovery, 3, 451–456.
Boyer, R. (2019). How scientific breakthroughs and social innovations shape the evolution of the healthcare sector. In S. Lechevalier (Ed.), Innovation beyond technology (pp. 89–119). Berlin: Springer.
Chatterjee, P. (1993). The nation and its fragments. Colonial and postcolonial histories. Princeton: Princeton University Press.
Cohen, F. J. (2005). Macro trends in pharmaceutical innovation. Nature Reviews Drug Discovery, 4, 78–84.
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22, 151–185.
Dumit, J. (2012). Drugs for life: How pharmaceutical companies define our health. Durham: Duke University Press.
Gaudillière, J.-P. (2014). An Indian path to biocapital? The Traditional Knowledge Digital Library (TKDL), drug patents and the reformulation regime of contemporary Ayurveda. East Asian Science Technology and Society, 8, 391–415.
Gaudillière, J.-P. (2015). Une manière industrielle de savoir. In C. Bonneuil & D. Pestre (Eds.), Histoire des sciences et des savoirs—3. Le siècle des technosciences, pp. 85–106. Paris: Le Seuil.
Gaudillière, J.-P. (in review). Innovation and its others: Pharmaceutical development, global capitalism and the dialectics of value. Biosocieties.
Gaudillière, J.-P., & Thoms, U. (Eds.). (2015). The development of scientific marketing in the twentieth century. New York: Pickering & Chatto.
Greene, J. (2007). Prescribing by numbers: Drugs and the definition of disease. Baltimore: The Johns Hopkins University Press.
Hughes, R. (2007). The innovation gap in pharmaceutical drug discovery and new models of R&D success. Kellogg School of Management. Accessible at http://www.kellogg.northwestern.edu/biotech/faculty/articles/newrdmodel.pdf.
Kneller, R. (2010). The importance of new companies for drug discovery: The origins of a decade of new drugs. Nature Reviews Drug Discovery, 9, 867–882.
Martin, P. (1999). Gene as drugs: The social shaping of gene therapy and the reconstruction of genetic disease. Sociology of Health & Illness, 21(5), 517–538.
Mukharji, P. (2011). Nationalizing the body. The medical market, print and daktari medicine. London: Anthem Press.
Mukharji, P. (2016). Doctoring traditions. Ayurveda, small technologies and braided sciences. Chicago: University of Chicago Press.
Munos, B. (2009). Lessons of 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery, 8, 959–968.
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery, 10, 428–438.
Pordié, L., & Gaudillière, J.-P. (2014). The reformulation regime in drug discovery: Revisiting poly-herbals and property rights in the Ayurvedic industry. East Asian Science Technology and Society, 8, 57–79.
Siegel Watkins, E. (2007). The estrogen elixir. A history of hormone replacement therapy in America. Baltimore: The Johns Hopkins University Press.
Souyri, P.-F. (2016). Moderne sans être occidental. Aux origines du Japon d’aujourd’hui. Paris: Gallimard.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Gaudillière, JP. (2019). From Crisis to Reformulation: Innovation in the Global Drug Industry and the Alternative Modernization of Indian Ayurveda. In: Lechevalier, S. (eds) Innovation Beyond Technology. Creative Economy. Springer, Singapore. https://doi.org/10.1007/978-981-13-9053-1_6
Download citation
DOI: https://doi.org/10.1007/978-981-13-9053-1_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-9052-4
Online ISBN: 978-981-13-9053-1
eBook Packages: Economics and FinanceEconomics and Finance (R0)